Body mass index increase, serum leptin, adiponectin, neuropeptide y and lipid levels during treatment with olanzapine and haloperidol

Pharmacopsychiatry

Volumn 44, Issue 5, 2011, Pages 169-172

  Raposo, N R B ^a,b   Ferreira, A S ^a   Gattaz, W F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

adiponectin; adverse effects; antipsychotic drugs; body mass index; leptin; neuropeptide Y

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN; NEUROPEPTIDE Y; OLANZAPINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HORMONE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NATURALISTIC INQUIRY; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPONECTIN; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOLOGICAL MARKERS; BODY MASS INDEX; HALOPERIDOL; HUMANS; LEPTIN; LIPIDS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 80051783468     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1280793     Document Type: Article

References (31)

1. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci: 1987; 499 203 215
2. Baptista T, Lacruz A, de Mendonza S et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry: 2000; 33 81 88 (Pubitemid 30346135)
3. Parsons B, Allison DB, Loebel A et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res: 2009; 110 103 110
4. Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry: 1999; 60 358 363 (Pubitemid 29289721)
5. Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry: 1999; 156 312 314 (Pubitemid 29077125)
6. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment pharmacological mechanisms. Pharmacol Ther: 2010; 125 169 179
7. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis: 2008; 18 158 168 (Pubitemid 351282471)
8. Jin H, Meyer JM, Mudaliar S et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res: 2008; 100 70 85
9. De Leon J, Susce MT, Jonhson M et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res: 2007; 92 95 102 (Pubitemid 46561228)
10. Mukherjee S, Decina P, Bocola V et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry: 1996; 37 68 73 (Pubitemid 26024880)
11. th edition Washington, DC American Psychiatric Press: 1994
12. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardization. Br J Psychiatry: 1989; 155 59 65 (Pubitemid 19270851)
13. Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl: 1998; 714 309 315 (Pubitemid 28386853)
14. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry: 2000; 61 742 749
15. Morimoto T, Yamamoto Y, Mobarakeh JI et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav: 1999; 67 679 683
16. Dryden S, Brown M, King P et al. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res: 1999; 31 363 366 (Pubitemid 29319121)
17. Meguid MM, Fetssov SO, Varma M et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition: 2000; 16 843 857
18. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry: 1998; 44 851 864 (Pubitemid 28520223)
19. Marquina D, Pea R, Fernndez E et al. Int Clin Psychopharmacol: 2011; 26 169 172
20. Nslund E, Hellstrm PM. Appetite signaling: From gut peptides and enteric nerves to brain. Physiol Behav: 2007; 92 256 262
21. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med: 1996; 334 292 295 (Pubitemid 26033933)
22. Foutaine RJ, Taylor AE, Mancuso JP et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity: 2010; 18 1646 1651
23. Kluge M, Schuld A, Schacht A et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrino: 2009; 34 118 128
24. Esen-Danaci A, Sarandi A, Tanellu F et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 1434 1438
25. Kim B, Sohn J, Park C et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci: 2008; 23 685 690
26. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol: 2010; doi: 10.1177/0091270010368678
27. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am: 2009; 32 775 794
28. Kolakowska T, Gadhvi H, Molyneux S. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int J Clin Psychopharmacol: 1987; 2 83 88
29. Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry: 1980; 136 287 289 (Pubitemid 10081829)
30. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep: 1980; 6 483 486
31. Ugur T, Bartels M, Kis B et al. Psychosis following anti-obesity treatment with rimonabant. Obes Facts: 2008; 1 103 105